TOPICS

Tag: Acne Vulgaris

Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX101 4% Minocycline Foam for Moderate-to-Severe Acne Vulgaris

J Clin Aesthet Dermatol. 2019;12(10):16–23 by Linda Stein Gold, MD; Sunil Dhawan, MD; Jonathan Weiss, MD; Zoe Diana Draelos, MD; Herman Ellman, MD; and Iain Stuart, PhD Dr. Stein Gold is with the Henry Ford Health System in Detroit, Michigan. Dr. Dhawan is with the Center for Dermatology Clinical Research, Inc., in Fremont, California. Dr. Weiss

CONTINUE READING »

Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short-Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac®) Cream 0.1%

by Srinivas Sidgiddi, MD; Kent Allenby, MD; Franklin Okumu, PhD; and Anirudh Gautam, MPharm Drs. Sidgiddi, Allenby, and Okumu are with Promius Pharma in Princeton, New Jersey. Mr. Gautam is with Dr. Reddy’s Laboratories SA in Basel, Switzerland. FUNDING: This study was funded and sponsored by Dr. Reddy’s Laboratories (DRL #841). DISCLOSURES: Dr. Sidgiddi, MD

CONTINUE READING »

Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-severe Acne Vulgaris in a Preadolescent and Adolescent Population

by Sharleen St. Surin-Lord, MD; Todd E. Schlesinger, MD, FAAD; and Eric Guenin, PharmD, PhD, MPH Dr. St. Surin-Lord is with Visage Dermatology and Aesthetics Center in Largo, Maryland. Dr. Schlesinger is with the Clinical Research Center of the Carolinas in Charleston, South Carolina. Dr. Guenin is with Ortho Dermatologics in Bridgewater, New Jersey. FUNDING: Ortho

CONTINUE READING »